Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-192

But the jump in ARDS patients from flu season in the US could accelerate the trial enrollment rate.

How?

When MSB global leader in allogeneic cellular medicines for inflammatory diseases,

announced today that the randomized controlled Phase 3 trial of remestemcel-L on top of maximal

care in ventilator-dependent patients with acute respiratory distress syndrome (ARDS) due to COVID-19 infection. has surpassed 50% enrollment. The trial’s primary endpoint is reduction in 30-day mortality relative to maximal care. ARDS continues to be the primary cause of death in COVID-19 patients.

Goal: on top of maximal

care in ventilator-dependent patients with acute respiratory distress syndrome (ARDS) due to COVID-19 infection.

Can't be enrolling everyone that is in the hospital with COVID-19. There are a bunch of other criteria that is not listed here but need to be met before we take them on.

Dont start roping in MSB using our set of ruler and built a cult following that will strangle MSB